Paper · 39706336

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.

Goyal L and 54 others. Ann Oncol, 2025. Cited by 37 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma. Papers, record 39706336. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39706336

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.; PubMed
Journal: Ann Oncol; PubMed
Year: 2025; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/39706336/; PubMed
DOI: https://doi.org/10.1016/j.annonc.2024.12.011; PubMed
The journal: https://conductscience.org/library/journal-index/9007735; PubMed
Citations, by iCite: 37; iCite
Relative citation ratio, by iCite: 8.87, provisional; iCite
Revised in PubMed: 2026-06-25; PubMed

Authors55

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Goyal L	L
2	DiToro D	D
3	Facchinetti F	F
4	Martin EE	E E
5	Peng P	P
6	Baiev I	I
7	Iyer R	R
8	Maurer J	J
9	Reyes S	S
10	Zhang K	K

1 to 10 of 55Source PubMed

See all 55 authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Cholangiocarcinoma	Major topic
Drug Resistance, Neoplasm	Major topic
Bile Duct Neoplasms	Major topic
Protein Kinase Inhibitors	Major topic
Receptor, Fibroblast Growth Factor, Type 2	Major topic
Receptors, Fibroblast Growth Factor	Major topic
Humans
Precision Medicine
Mutation
Female
Male
Middle Aged
Aged

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by23

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 37 citations.

PMID	Title	Journal	Year	In Papers	Source
42,679,332	Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.	JCO Precis Oncol	2026	https://conductscience.org/library/papers/42679332	PubMed
42,675,086	Discovery of a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.	Nat Commun	2026	https://conductscience.org/library/papers/42675086	PubMed
42,621,139	The role of FGFR signaling in SCLC and NSCLC: Current insights and therapeutic perspectives.	iScience	2026	https://conductscience.org/library/papers/42621139	PubMed
42,587,090	Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma.	Nat Rev Clin Oncol	2026	https://conductscience.org/library/papers/42587090	PubMed
42,489,683	Multikinase Inhibition with Tinengotinib in Advanced Solid Tumors: Results from a Multicenter Phase Ib/II Trial.	Clin Cancer Res	2026	https://conductscience.org/library/papers/42489683	PubMed
42,442,510	Molecular Subtypes of Cholangiocarcinoma and Their Translational Implications.	Gastroenterology	2026	https://conductscience.org/library/papers/42442510	PubMed
42,225,836	Mutation-centric kinase drug repurposing for rare cancers.	Nat Rev Cancer	2026	https://conductscience.org/library/papers/42225836	PubMed
42,146,765	Research on Targeted Therapy for Malignant Tumors of the Biliary Tract.	Onco Targets Ther	2026	https://conductscience.org/library/papers/42146765	PubMed
42,115,188	The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.	Nat Commun	2026	https://conductscience.org/library/papers/42115188	PubMed
42,010,121	Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing.	Nat Biotechnol	2026	https://conductscience.org/library/papers/42010121	PubMed

1 to 10 of 23

See all 23 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes
FGFR2	2,263	PubTator's text mining	https://conductscience.org/library/genes/2263

Source NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39706336

GET https://conductscience.org/api/papers/v1/39706336/authors?page=2

API reference For AI assistants